Investors finally get a glimpse of Denali Therapeutics Inc (DNLI) volume hitting the figure of 2.08 million.

On Tuesday, Denali Therapeutics Inc (NASDAQ: DNLI) was -12.63% drop from the session before settling in for the closing price of $15.99. A 52-week range for DNLI has been $10.57 – $33.33.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

A company in the Healthcare sector has jumped its sales by 260.06% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -13.07%. With a float of $125.73 million, this company’s outstanding shares have now reached $142.63 million.

In an organization with 422 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.

Denali Therapeutics Inc (DNLI) Insider and Institutional Ownership

Also, it is sometimes useful to examine the sentiment of large-scale investors toward Denali Therapeutics Inc stocks. The insider ownership of Denali Therapeutics Inc is 13.43%, while institutional ownership is 87.91%. The most recent insider transaction that took place on Jan 06 ’25, was worth 247,796. In this transaction Chief Medical Officer of this company sold 12,255 shares at a rate of $20.22, taking the stock ownership to the 178,580 shares. Before that another transaction happened on Jan 07 ’25, when Company’s Chief Medical Officer sold 2,907 for $20.81, making the entire transaction worth $60,495. This insider now owns 175,673 shares in total.

Denali Therapeutics Inc (DNLI) Latest Financial update

According to the Wall Street analysts, stocks earnings will be around -13.07% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.89% during the next five years compared to -4.46% drop over the previous five years of trading.

Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators

You can see what Denali Therapeutics Inc (DNLI) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.46.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.58, a number that is poised to hit -0.71 in the next quarter and is forecasted to reach -2.63 in one year’s time.

Technical Analysis of Denali Therapeutics Inc (DNLI)

Let’s dig in a bit further. During the last 5-days, its volume was 1.42 million. That was better than the volume of 1.28 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 48.01%. Additionally, its Average True Range was 1.07.

During the past 100 days, Denali Therapeutics Inc’s (DNLI) raw stochastic average was set at 22.80%, which indicates a significant decrease from 35.62% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 83.58% in the past 14 days, which was higher than the 76.87% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $14.76, while its 200-day Moving Average is $22.18. However, in the short run, Denali Therapeutics Inc’s stock first resistance to watch stands at $15.46. Second resistance stands at $16.94. The third major resistance level sits at $17.72. If the price goes on to break the first support level at $13.19, it is likely to go to the next support level at $12.41. The third support level lies at $10.93 if the price breaches the second support level.

Denali Therapeutics Inc (NASDAQ: DNLI) Key Stats

There are 145,242K outstanding shares of the company, which has a market capitalization of 2.03 billion. As of now, sales total 0 K while income totals -422,770 K. Its latest quarter income was 0 K while its last quarter net income were -114,750 K.